Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous reviews have shown that β-blocker use for the treatment of hypertension without compelling indications was associated with increased risk of stroke in the elderly. It remains unclear whether this increased risk was driven by the type of β-blocker. We sought to compare the efficacy of atenolol vs nonatenolol β-blockers in clinical trials enrolling young (< 60 years) and older patients with hypertension. METHODS: The Cochrane and MEDLINE databases were searched (January 2006-May 2013) for randomized trials evaluating stroke, myocardial infarction, death, or composite cardiovascular end points. Twenty-one hypertension trials with data on 145,811 participants were identified: 15 used atenolol, 7 were placebo-controlled trials, and 14 were active comparator trials. There were no trials of newer generation β-blockers identified. RESULTS: Among the elderly, atenolol was associated with an increased risk of stroke (relative risk [RR], 1.17; 95% confidence interval [CI], 1.05-1.30) compared with other antihypertensive agents. The risk of stroke for nonatenolol β-blockers compared with other agents (RR, 1.22; 95% CI, 0.99-1.50) did not reach statistical significance in the elderly. In the young, atenolol was associated with reduced risk of stroke compared with other agents (RR, 0.78; 95% CI, 0.64-0.95), whereas nonatenolol β-blockers were associated with a lower risk of composite cardiac events (RR, 0.86; 95% CI, 0.75-0.996) compared with placebo, with no significant difference in events compared with active controls. CONCLUSIONS: In the young, both atenolol and nonatenolol β-blockers are effective in reducing cardiovascular end points for hypertension without compelling indications. Atenolol is associated with increased stroke in the elderly but whether this extends to nonatenolol β-blockers remains uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Dahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290 · cited 1×
“Atenolol is also associated with an increased risk of diabetes mellitus relative to nonatenolol b-blockers and an increased risk of stroke and total mortality overall in patients with hypertension when compared with other antihypertensive agents.(7) Although the effects of age on outcomes with b-blocker use have been…”
Cited by
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
The Mediterranean Diet, its Components, and Cardiovascular Disease
Widmer, R. J., Flammer, A. J., Lerman, L. O., & Lerman, A. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.10.014 · Cited by 963
“Estimates of lifestyle modifications such as the Mediterranean diet as a whole,(12) fruits and vegetables,(3-5) smoking cessation,(9) moderate alcohol,(11) omega-3 fatty acids,(16) and improved physical activity(8) have substantial benefits for CVD prevention not seen with commonly used standard medical therapies such…”
MethodBeta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., & Opie, L. H. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub5 · Cited by 474
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
β-blockers: Their new life from hypertension to cancer and migraine
Fumagalli, C., Maurizi, N., Marchionni, N., & Fornasari, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104587 · Cited by 102
Metadata
- Authors
- Kuyper, L. M., & Khan, N. A.
- Venue
- Canadian Journal of Cardiology
- Publisher
- Elsevier BV
- Published
- 2014-05
- Volume
- 30
- Issue
- 5
- Pages
- S47-S53
- ISSN
- 0828-282X (ISSN-L)
- OpenAlex
- W2098006477
- Cited by
- 66
- References
- 3
- FWCI
- 1.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. https://app.cochat.ai/papers/10.1016/j.cjca.2014.01.006
- The paper
- Kuyper, L. M., & Khan, N. A. (2014). Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2014.01.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.